Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

VectivBio Holding AG VECT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • CH • USD

SharesGrow Score
43/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$18.00
+6.7%

VectivBio Holding AG (VECT) is a Biotechnology company in the Healthcare sector, currently trading at $16.87. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is VECT = $18 (+6.7% upside).

Financials: revenue is $27M, +0%/yr average growth. Net income is $94M (loss), growing at -69.5%/yr. Net profit margin is -342.8% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $10M against $213M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 9.14 (strong liquidity). Debt-to-assets is 4.1%. Total assets: $253M.

Analyst outlook: 3 / 3 analysts rate VECT as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 58/100 (Partial), Future 88/100 (Pass), Income 10/100 (Fail).

$18.00
▲ 6.7% Upside
Average Price Target
The 12-month price target for VectivBio Holding AG is $18.00.

VECT SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 60/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 88/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VECT

✓
VALUE Pass
60/100
VECT trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $18, implying +6.7% from the current price $17. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
VECT: +0%/yr revenue is, -69.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet VECT: Debt-to-Equity (D/E) ratio 0.05 (conservative), Current ratio is 9.14 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
VECT: Gross margin is 100% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
88/100
Analyst outlook: 3 / 3 analysts rate VECT as buy (100%). Analyst consensus target is $18 (+6.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
VECT: Net profit margin is -342.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range4.25-16.98
Volume127.65K
Avg Volume (30D)1.1M
Market Cap$1.06B
Beta (1Y)0.10
Share Statistics
EPS (TTM)-2.12
Shares Outstanding$44.13M
IPO Date2021-04-08
CEOLuca Santarelli
Financial Highlights & Ratios
Revenue (TTM)$27.34M
Gross Profit$27.34M
EBITDA$-79.85M
Net Income$-93.74M
Operating Income$-80.52M
Total Cash$221.42M
Total Debt$10.46M
Net Debt$-210.95M
Total Assets$252.6M
Price / Earnings (P/E)-8
Price / Sales (P/S)38.75
Analyst Forecast
1Y Price Target$18.00
Target High$18.00
Target Low$18.00
Upside+6.7%
Rating ConsensusBuy
Analysts Covering3
Buy 100% Hold 0% Sell 0%
Company Info
CountryCH
ExchangeNASDAQ Global Select
CurrencyUSD

Price Chart

Track all markets on TradingView
VECT
VectivBio Holding AG ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
4.25 52WK RANGE 16.98

People Also View

IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
 CNSP
CNSP
CNS Pharmaceuticals, Inc.
$2.64
+5.18%
 CWBR
CWBR
CohBar, Inc.
$0.41
+0.00%
 ENVB
ENVB
Enveric Biosciences, Inc.
$1.95
-1.02%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message